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Abstract: Alternatives to the well-established capsular polysaccharide-based vaccines 
against Streptococcus pneumoniae that circumvent limitations arising from limited serotype 
coverage and the emergence of resistance due to capsule switching (serotype replacement) 
are being widely pursued. Much attention is now focused on the development of recombinant 
subunit vaccines based on highly conserved pneumococcal surface proteins and virulence 
factors. A further step might involve focusing the host humoral immune response onto 
protective protein epitopes using as immunogens structurally optimized epitope mimetics. 
One approach to deliver such epitope mimetics to the immune system is through the  
use of synthetic virus-like particles (SVLPs). SVLPs are made from synthetic coiled-coil 
lipopeptides that are designed to spontaneously self-assemble into 20–30 nm diameter 
nanoparticles in aqueous buffer. Multivalent display of epitope mimetics on the surface of SVLPs 
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generates highly immunogenic nanoparticles that elicit strong epitope-specific humoral 
immune responses without the need for external adjuvants. Here, we set out to demonstrate 
that this approach can yield vaccine candidates able to elicit a protective immune response, 
using epitopes derived from the proline-rich region of pneumococcal surface protein A 
(PspA). These streptococcal SVLP-based vaccine candidates are shown to elicit strong 
humoral immune responses in mice. Following active immunization and challenge with 
lethal doses of streptococcus, SVLP-based immunogens are able to elicit significant 
protection in mice. Furthermore, a mimetic-specific monoclonal antibody is shown to 
mediate partial protection upon passive immunization. The results show that SVLPs 
combined with synthetic epitope mimetics may have potential for the development of an 
effective vaccine against Streptococcus pneumoniae. 
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1. Introduction 
Streptococcus pneumoniae is a major cause of disease in humans including severe meningitis, otitis 
media, pneumonia, and sepsis [1,2]. Millions of individuals die of diseases caused by S. pneumoniae 
every year, and most of these deaths occur in developing countries [3]. Pathogenic pneumococci produce 
structurally and antigenically diverse polysaccharide capsules that can be used to identify more than 90 
immunochemically distinct serotypes. The isolated capsular pneumococcal polysaccharides (CPPs) have 
been used for many years as vaccines to confer serotype-specific, antibody-mediated protection against 
invasive pneumococcal disease. However, CPPs alone are typically poorly immunogenic, elicit mostly  
IgM-type antibodies, induce weak protection in children and fail to elicit long-lasting memory responses 
in adults [4,5]. Second-generation pneumococcal vaccines composed of isolated capsular polysaccharide 
conjugated to carrier proteins (PCPs) result in improved T-cell dependent immune responses [6,7]. Since 
their introduction in the 1990s, marketed PCP vaccines have proven highly effective in combating 
invasive pneumococcal disease [8,9]. However, their production requires a complex manufacturing 
process [10], they can be poorly thermostable [11] and may confer only poor or variable levels of 
protection in some population groups [12] and against some disease states, including total pneumococcal 
meningitis and total pneumococcal otitis media [4]. Moreover, PCP vaccines offer only limited serotype 
coverage and their use promotes serotype replacement and emergence of highly virulent capsule switch 
variants expressing altered capsule polysaccharides not covered by the vaccine [13–15]. Consequently, 
there is a pressing need for the development of alternative serotype-independent pneumococcal vaccines. 
One promising approach focuses on the development of recombinant subunit vaccines using highly 
conserved pneumococcal surface proteins and virulence factors [4,5,16,17], which can be administered 
together with an immunostimulatory adjuvant [16,17]. Difficulties can arise, however, when the 
recombinant proteins are unstable or incorrectly folded and/or direct immune responses towards 
immunodominant polymorphic epitopes irrelevant for protection, while avoiding immune responses 
against neutralizing conserved epitopes [18]. 
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We explore here an alternative approach, using synthetic epitope mimetics as antigens to focus 
immune responses onto conserved protective B-cell epitopes. The mimetics are delivered to the immune 
system using synthetic virus like particles (SVLPs). SVLPs arise from synthetic coiled-coil lipopeptides 
(CCLs) that are designed to spontaneously self-assemble into nanoparticles in aqueous buffer. The coiled 
coil directs formation of parallel trimeric helical bundles, and the lipid tail in each CCL drives formation 
of 20–30 nm diameter nanoparticles, through association of around 24 trimeric helical bundles and burial 
of the lipid chains in a central micelle-like core. A B-cell epitope mimetic conjugated to each CCL can 
then be displayed in a multivalent format (ca. 70 copies) over the outer surface of the nanoparticle 
(Figure 1A) [19–21]. In addition, each CCL is designed to include selected T cell epitopes along with a 
toll-like receptor ligand, such as the lipids Pam2/3-Cys [20,22]. The inclusion of T-cell epitopes and 
ligands for pattern recognition receptors should aid the tailored activation of both innate and adaptive 
immunity. An additional feature is that the manufacturing process for SVLP vaccines is based entirely on 
synthetic chemistry, which gives products of well-defined composition, high purity and thermal stability, 
and no external adjuvant is used. This is in contrast to VLPs based on viral capsid proteins in established 
vaccines targeting hepatitis B and E, as well as human papilloma virus, which require challenging cell-
based methods for production and purification, and administration with an alum adjuvant to boost 
immunogenicity [23–25]. 
In this work, epitope mimetics based on pneumococcal surface protein A (PspA), displayed on the 
surface of the SVLPs, have been tested as vaccine candidates for their ability to provide protection 
against pneumococcal infection. An overview of the work-flow undertaken is given in Figure 2. 
PspA is a well-studied subunit pneumococcal vaccine candidate [16]. During invasive systemic 
infection, PspA interferes with the deposition of complement on the pneumococcal surface, and during 
mucosal infection PspA protects the bacteria from killing by human lactoferrin [26–29]. PspA contains 
a variable -helical N-terminal domain, an antigenically conserved proline-rich region (PRR), which is 
often interrupted by a non-proline block (NPB), and a choline-binding domain that anchors the protein 
to the bacterial outer cell wall [30,31]. Antibodies to PspA are capable of protecting mice against lethal 
infection with S. pneumoniae (reviewed in [16]) and protective B-cell epitopes have been found within 
the polymorphic N-terminal domain as well as in the PRR [31–33]. In particular, antibodies specific for 
the semi-conserved PRR have been found to provide cross-protection against a broad spectrum of 
pneumococcal strains. This work explores the properties of SVLPs assembled from CCLs carrying  
B-cell epitope mimetics from the PRR of PspA. These SVLPs are shown to be highly immunogenic in 
mice without additional adjuvants, where they elicit S. pneumoniae cross-reactive antibodies and 
generate significant protective humoral immune responses. 
2. Methods and Materials 
2.1. Synthesis of Peptides and Coiled-Coil Lipopeptides 
The CCL used in this work is shown in Figure 1A, and was synthesized as described earlier [20].  
The epitope mimetics studied are linear peptides from the PRR or NPB of PspA (shown in Figure 1B). 
The linear sequences were synthesized by Fmoc-solid-phase peptide synthesis [34], using either Rink 
amide MBHA resin (for C-terminal amides) or chlorotrityl chloride resin (for peptides with a carboxylic 
acid terminus) (Novabiochem, Merck-Millipore, Darmstadt). For N-linked mimetics (NPB, PR1 and PR2/N), 
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Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanic acid (Fmoc-NH-PEG6-COOH, Novabiochem, 
Merck-Millipore, Darmstadt, Germany) as linker was coupled to the N-terminus of the resin-bound 
peptide. The Fmoc group was then removed with 20% piperidine in DMF and 3-maleimidopropionic 
acid (Sigma-Aldrich, St Louis, MO, USA) was coupled to the new N-terminus. After cleavage from the 
resin and side-chain deprotection under standard conditions [34], the products were purified by HPLC 
(C18 column, 10%–40% MeCN in H2O (+0.1% CF3COOH). Each product was >95% pure by analytical 
HPLC. Analysis by MALDI-TOF-MS: PR1, m/z [M + H]+ 3609.7, calc. 3609.1; PR2/N, m/z [M + H]+ 
2888.8, calc. 2889.3; NBP m/z [M + H]+ 4071.0, calc. 4072.3. 
 
(A) 
 
(B) 
Figure 1. Components and their self-assembly into SVLPs. (A), SVLPs are composed of  
a synthetic coiled-coil lipopeptide (CCL), which contains a heptad repeat (IEKKIEA)4 
linked to a promiscuous T helper epitope (underlined) and to the TLR-2/6 ligand Pam2Cys. 
B-cell epitope mimetics can be conjugated to the unique Cys, as shown. The C-terminal  
a-NH2 is D-Ala-amide to protect against digestion with carboxypeptidases. The CCLs form 
trimeric helical bundles that self-assemble into 20–30 nm diameter nanoparticles (SVLPs) 
with a lipid-chain core; (B) In this work, PRR-derived peptides were linked through either 
the N- or C-terminus (represented in the sequences by x and z, respectively) to the unique 
Cys of the CCLs using the linkers shown in (A). 
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Figure 2. Testing of a potential SVLP-based pneumococcal vaccine candidate. Designed 
coiled-coil lipopeptides carrying segments of PspA were made by chemical synthesis (top, 
left). Laboratory mice were immunized with the resulting SVLPs. The murine immunological 
responses to the SVLPs were analyzed to determine S. pneumoniae cross-reactive antibody 
responses and to generate mAbs. Challenge experiments were used to evaluate protective 
humoral immune responses. 
For the C-terminal conjugate (PR2/C), the assembled peptide chain was acetylated at the N-terminus 
before cleavage from the resin with CF3CH2OH/CH2Cl2 (1:4). After concentration in vacuo, the side-chain 
protected peptide was precipitated with cold Et2O, washed and dried. (2-Aminoethyl)maleimide 
(Sigma-Aldrich, St. Louis, MO, USA) was coupled to the C-terminus in DMF using HATU/HOAt/iPr2EtN. 
After concentration in vacuo and precipitation with Et2O, the peptide was washed and dried. The side 
chain protecting groups were then removed under standard conditions [34], and the product was purified 
by HPLC (C18 column, 10%–100% MeCN in H2O (+0.1% CF3COOH); >95% pure by analytical HPLC. 
Analysis by ES-MS: m/z [M + H]+ 2483.2, calc. 2484.8. 
For conjugation of each epitope mimetic to the CCL, the CCL (6.0 mg, 0.9 μmol) and epitope mimetic 
(1.3 μmol) in H2O/MeCN (1:1, 5 ml) at pH 6.5–7.0, was stirred for 2 h at room temp. The conjugate was 
then purified by HPLC using a C4 preparative column with 50%–100% MeCN in H2O (+0.1% TFA); 
each conjugate purity was >95%. For CCL-PR1, MALDI-TOF MS, m/z [M + H] 10406.8, calc. 10405.6. 
For CCL-NPB, MALDI-TOF MS, m/z [M +H] 10869.8 Da, found 10872.3. For CCL-PR2/N, 
MALDI-TOF MS m/z [M + H] 9686.2, calc. 9685.6; for CCL-PR2/C, MALDI-TOF MS, m/z [M + H] 
9280.2, calc. 9280.2. 
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The conjugates in phosphate buffered saline (PBS) were analyzed by dynamic light scattering (Wyatt 
DynaPro, Wyatt Technologies, Santa Barbara, CA, USA) at 25 °C. The mean hydrodynamic radius 
(Rh in nm) and polydispersity (%Pd) were 12 nm and 12.3% for CCL-PR1; 12 nm and 13.0% for  
CCL-PR2/N; 11 nm and 16% for PR2/C; 14 nm and 13% for CCL-NPB. 
Each epitope-CCL conjugate was dissolved in sterile PBS and equilibrated for 40 min at room 
temperature with occasional mixing, prior to immunizations. 
2.2. Cloning and Expression of the PRR from PspA Strain 1577 (rPspA) 
An internal 312 bp fragment of pspA from S. pneumoniae strain 1577 was amplified by PCR using 
the following primers, cloned between Nco I and Sal I restriction sites in pET32a (Novagen) and 
expressed as a thioredoxin (Trx) fusion protein (called rPspA), as described earlier [31]: 
PspA-for: 5'-GGGAGCCATGGCTGACCTTAAGAAAGCAGTTAATGAGCCA-3' 
PspA-rev: 5'-CCGTCGACACTACATACCGTTTTCTTGTTTCCAGCC-3' 
The plasmid was introduced into E. coli BL21(DE3) and rPspA was expressed in LB medium. The 
full amino acid sequence of the fusion protein is given in the Appendix (Figure A1). rPspA expression 
was induced at OD600 0.6–0.9 by addition of IPTG (0.1 mM). Induced cells (3 h at 37 °C) were harvested 
and lysed by sonication in 20 mM Tris pH 8, 500 mM NaCl, 10 mM imidazole (buffer A) containing a 
protease inhibitor cocktail (Roche, Basel, Switzerland) and DNAse. Lysate was loaded onto a Ni-NTA 
1 mL Superflow cartridge (Qiagen, Venlo, The Netherland), non-bound proteins washed out with  
buffer A and rPspA eluted with buffer containing 300 mM imidazole, purified by size-exclusion 
chromatography (Superdex 200 10/300 GL) in 20 mM Tris pH 7.5, 150 mM NaCl. SDS-PAGE revealed 
a single band with an apparent molecular weight of 30 kDa. For immunizations, rPspA was concentrated 
and filtered using a 0.2 μm filter, dialyzed into Hanks’ Balanced Salt solution (HBSS) and adsorbed to 
alum (Imject Alum, Pierce Biotechnology, Rockford, IL, USA). Briefly, Imject alum was added 
dropwise with constant mixing to the rPspA solution. Mixing was continued for 30 min to allow alum 
to effectively adsorb antigen. The final volume ratio of Imject alum to protein solution was 1:1. 
2.3. Pneumococcal Strains 
Clinical isolates of S. pneumoniae (Table 1) were collected during surveillance studies in Ghana or 
in Papua New Guinea (PNG). Isolates from PNG were obtained from the Papua New Guinea Institute 
of Medical Research (IMR), Goroka. S. pneumoniae colonies were identified on the basis of colony 
morphology. All pneumococcal isolates were serotyped by a sequential multiplex PCR as described [35]. 
The DNA sequence of pspA in each strain was determined using the primers given in the Appendix 
Table A1. 
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Table 1. Cross-reactivity of immune-sera with genetically diverse pneumococcal clinical isolates in flow-cytometric analyses. Capsular 
serotypes and pspA allelic variants that have been classified into clades according to [30] are shown. (+ = surface staining;  = no surface 
staining). A maximum likelihood phylogenetic tree of the PRR sequences of the 10 tested S. pneumoniae clinical isolates and of 44  
S. pneumoniae genomes from the NCBI database is shown in the Appendix (Figure A2). CSF = Cerebrospinal fluid. 
Strain 
Diagnosis 
of 
Patient 
Site of 
Isolation 
Origin 
Year 
Isolated
pspA 
Clade
Capsule 
Type 
Non-Proline 
Block 
Cross-Reactivity of Sera Induced by Immunogen 
CCL-NPB CCL-PR1 
CCL-
PR2/N 
CCL-
PR2/C 
1577 case CSF Ghana 2009 1 1 present + + + + 
233 case CSF PNG, Chimbu 1997 1 4 present + + + + 
716 case CSF PNG, Lufa 1999 1 5 present + +   
920 carriage Naso-pharynx 
PNG, Eastern 
Highlands 
2006 1 8 present + + + + 
1388 case CSF PNG, Lufa 2002 2 4 present + + + + 
932 case CSF PNG, Goroka 1999 3 6A/B absent  + + + 
839 case CSF PNG, Ung/Bena 1999 3 7F absent   + + 
1260 case CSF PNG, Goroka 2001 4 4 present + +   
1272 case CSF PNG, Daulo 2002 5 2 present + + + + 
4408 carriage Naso-pharynx 
PNG, Eastern 
Highlands 
2010 5 19A present + + + + 
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2.4. Animal Studies 
Animal experiments were carried out in accordance with the national rules and regulations for the 
protection of animal rights. The protocols were ethically approved by the veterinary office of the county 
of Basel-City, Switzerland. 
Six to eight week-old specific pathogen-free HsdWin:NMRI outbred mice were purchased from 
Harlan Laboratories B.V. (The Netherlands) and used for immunizations and for pneumococcal 
protection studies. For immunogenicity studies, mice received two subcutaneous injections (100 μL)  
of 20 μg of recombinant PspA formulated with Imject alum, or SVLPs in PBS without adjuvant, at 
three-week intervals. The used SVLP immunization dose was selected based upon preliminary  
dose-finding studies in NMRI mice. Blood was collected before the first injection and 10 days after the 
final injection. Negative controls received the same course of sterile PBS. 
The protective efficacy of SVLPs was evaluated in an experimental mouse model of acute infection 
in which mice were challenged intravenously (i.v.) via the tail vein with a lethal dose (approximately 
104 CFUs) of a serotype 1 clinical isolate (1577). Pneumococci recovered from the blood of intraperitoneally 
infected mice were used to prepare bacterial stock cultures. The mouse-passaged pneumococcal strain 
was grown overnight on blood agar plates (Columbia agar with sheep blood, Oxoid GmbH) at 37 °C  
in 5% CO2. Pneumococci were harvested with a loop, resuspended in sterile HBSS and adjusted to  
1 × 105 CFUs/mL before administration. After challenge the animals were monitored for 14 days for 
signs of illness. Mice were euthanized when they exhibited ruffled fur, hunched back, paralysis or other 
symptoms. Mouse survival curves were evaluated statistically by the log rank (Mantel-Cox) test using 
GraphPad Prism Software (version 6.0 for Windows, GraphPad Software, Inc., La Jolla, CA, USA).  
A P value of 0.05 was considered statistically significant. 
2.5. Generation of Hybridoma Cell Lines Producing Epitope Mimetic-Specific mAbs 
Cells from the spleen of a CCL-PR2/N (Figure 1B) immunized mouse were fused with PAI mouse 
myeloma cells as a fusion partner. Hybrids were selected in hypoxanthine-aminopterin-thymidine 
(HAT) medium, and B-cell hybridoma lines secreting peptide-specific IgG were identified by peptide 
ELISA. For large-scale mAb production, cloned hybridoma cell lines were cultured in 175 cm2 flasks 
and mAbs were purified by protein A affinity chromatography (HiTrap rProtein A FF, Amersham 
Biosciences AB, Uppsala, Sweden). Purified mAbs were dialyzed against PBS, sterile-filtered, and stored 
at 80 °C. 
2.6. Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA MaxiSorp microtitre plates (Thermo Fisher Scientific, Nunc A/S, Roskilde, Denmark) were 
coated at 4 °C overnight with peptide in PBS (50 μL; 5 μg/mL). Wells were blocked with 5% milk 
powder in PBS for 1 h at room temperature and washed 3 × with PBS containing 0.05% Tween 20. Plates 
were then incubated with serial dilutions of mouse sera in PBS for 1 h at room temperature. After washing, 
plates were incubated with alkaline phosphatase-conjugated goat anti-mouse IgG (-chain-specific) 
antibodies (Sigma, St. Louis, MO, USA) for 1 h at room temperature and then washed. Phosphatase 
substrate (1 mg/mL p-nitrophenyl phosphate) in buffer (0.14% Na2CO3, 0.3% NaHCO3, 0.02% MgCl2) 
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was added and incubated at room temp. The optical density (OD) of the reaction product was recorded 
after an appropriate time at 405 nm using a microplate reader (Sunrise, Tecan Trading AG, Männedorf, 
Switzerland). Endpoint titer is the last serum dilution where the ODtest serum  mean ODPBS plus two times 
the standard deviation. In competition assays, immune-sera or mAbs were pre-incubated with increasing 
concentrations of competitor peptides in PBS for 30 min. Equilibrated antibody-peptide solutions were 
transferred to peptide-coated ELISA plates and processed as described above. 
2.7. SDS-PAGE and Immunoblotting 
S. pneumoniae isolates were grown overnight on blood agar plates, collected and washed once in 
sterile PBS. Pelleted bacteria (4.25 × 107 CFUs) were lysed in 100 L sample buffer (Laemmli buffer, 
Bio-Rad Laboratories, Inc. Hercules, CA, USA) and heated to 95 °C for 10 min. before loading on  
4%–12% Bis-Tris gels. Following gel electrophoresis, separated proteins were electrophoretically 
transferred to a nitrocellulose membrane. Blots were blocked with PBS containing 5% milk powder for 
1 h at room temperature or overnight at 4 °C. The membrane was incubated with appropriate dilutions 
of mouse serum or mAbs in PBS for 1 h at room temperature. In competition experiments, primary 
antibodies were pre-incubated for 30 min. with a competitor peptide at a concentration of 1, 0.1 or  
0.01 g/mL. After several washing steps, filter strips were incubated with goat anti-mouse IgG 
horseradish peroxidase conjugated Ig (0.1 g/mL; Bio-Rad Laboratories, Inc. Hercules, CA, USA) for 
1 h. Blots were developed using the ECL (Pierce) system according to manufacturer’s instructions. 
2.8. Surface Staining of Bacterial Cells 
S. pneumoniae isolates were grown overnight on blood agar plates or in liquid medium (Bacto Todd 
Hewitt Broth supplemented with Bacto yeast extract), collected and resuspended in sterile PBS. For flow 
cytometry experiments, pelleted bacteria were inactivated in formalin (1 mL) for 30 min at room 
temperature and blocked for 30 min at 4 °C with blocking solution containing fatty acid-free bovine 
serum albumin (BSA) in PBS (5 mg/mL). Fixed bacteria (7.2 × 105 CFUs per sample) were stained with 
mouse immune-sera or mAbs for 1 h at room temperature. Surface bound IgG was detected with  
Alexa-Fluor 488-conjugated goat anti-mouse IgG antibodies (Invitrogen). Cell pellets were resuspended 
in 400 μL FACS flow and bacterial staining was analysed by using a FACS Calibur cytometer (Becton 
Dickinson, Hongkong, China). 
For immunofluorescence microscopy, 30 μL droplets of formalin solution were placed into each well 
of a pre-coated Poly-L-Lysin microscope glass slide. Ten microliters of a bacterial suspension containing 
approximately 2.6 × 108 CFUs were added to each well and incubated for 30 min at room temp. After 
washing, wells were blocked with 1% BSA in PBS. Immunostaining was performed by incubating the 
wells with an appropriate mAb or serum dilution in blocking solution for 1 h at room temperature.  
After washing, cells were incubated with secondary antibodies specific for mouse IgG conjugated with 
Alexa-Fluor 488. Before the immunoreactivity was analyzed with a fluorescence microscope, the wells 
were washed, mounted with ProLong® Gold antifade reagent (Invitrogen) and covered with a coverslip. 
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3. Results 
3.1. Design and Synthesis of Epitope-Loaded SVLPs 
Protective epitopes have been identified within the PRR of PspA [31,36]. For our work, two epitopes 
(PR1 and NPB) were selected from the PRR of a serotype 1 pneumococcal strain (1577) (Figure 1B). A 
second epitope (PR2) derived from a heterologous PRR was also selected. For the generation of 
epitope-loaded SVLPs, linear peptides representing the PR1 and NPB epitopes were each coupled 
through the N-terminus to the CCL building block (Figure 1A). The conjugates are denoted CCL-PR1 
and CCL-NPB (Figure 1B). The PR2 peptide was coupled via a linker to the CCL in either N- or  
C-terminal orientations, yielding two additional constructs (CCL-PR2/N and CCL-PR2/C, see Figure 1B). 
The CCL building block, described in earlier work [20], contains the isoleucine zipper (IEKKIEA)4, 
which directs formation of thermally stable parallel trimeric helical bundles [37]. The isoleucine zipper 
is fused to a CD4 T helper epitope. In this case, a promiscuous T helper epitope was chosen, derived 
from the circumsporozoite surface protein of the malaria parasite Plasmodium falciparum (Figure 1A), 
since this epitope is recognized by T cells in association with most mouse and human MHC class II 
molecules [38,39]. The CCL is therefore expected to elicit T helper responses in the mouse infection 
model used in this work, as well as in humans. As in earlier studies [19–22], self-assembly of the  
CCL-epitope conjugates into SVLPs was confirmed by dynamic light scattering measurements, which 
showed narrow nanoparticle size distributions with mean hydrodynamic radii (Rh) in the range of  
12–14 nm and polydispersity (%Pd) values between 12.3% and 16%. 
3.2. Immunogenicity of Epitope-Loaded SVLPs in Mice 
NMRI outbred mice (10 per group) were immunized twice with 20 μg doses of each SVLP construct: 
CCL-PR1, CCL-NPB, CCL-PR2/N, CCL-PR2/C or a mixture of CCL-NPB + CCL-PR1, each in PBS 
without adjuvant. ELISA of sera collected pre-immune and after the second immunization showed that 
most mice developed strong antigen-specific IgG responses against the target peptide (Figure 3). SVLPs 
comprising a mixture of CCL-NPB and CCL-PR1 elicited high antibody titers against both the NPB and 
the PR1 epitopes. The CCL-PR2/C construct elicited lower titers of PR2-specific IgG antibodies 
compared to CCL-PR2/N (p = 0.0065). Pre-immune sera showed no reactivity in ELISA. 
3.3. Cross-Reactivity of Induced Antibodies with S. Pneumoniae PspA 
Cross-reactivity of serum IgGs raised against the peptide-loaded SVLPs with the endogenous protein 
expressed by S. pneumoniae was investigated by immunoblotting and flow-cytometry analysis. The 
molecular mass of PspA ranges between 67 kDa and 98 kDa in various pneumococcal strains [40]. With 
the S. pneumoniae 1577 clinical isolate, immune sera stained a double band with an apparent molecular 
weight of around ~70 kDa. In Western blot competition experiments, the binding of immune sera to the 
endogenous protein was inhibited by the corresponding synthetic peptide in a concentration dependent 
manner (Figure 4A), thereby confirming the specificity of the binding. Flow-cytometry analyses with 
formalin-inactivated bacteria showed the development of surface-binding IgG antibodies in sera from 
immunized mice. Surface staining of cells with PspA specific antibodies was assessed using bacteria 
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grown on blood agar plates as well as bacteria harvested from liquid cultures. Both preparations yielded 
similar results in flow cytometry experiments. Representative results are shown with serum of a  
CCL-PR2/N immunized mouse in Figure 4B. While all mice receiving CCL-NPB alone or in combination 
with CCL-PR1 sero-converted in immunoblotting and flow-cytometry analyses, lower rates of  
sero-conversion were observed after immunization with CCL-PR1, CCL-PR2/N or CCL-PR2/C (Figure 4C). 
None of the pre-immune mouse sera was positive in flow-cytometry or Western blot analysis.  
 
Figure 3. Anti-peptide IgG response in NMRI mice. Female NMRI mice (6–8 weeks of age) 
were immunized twice with SVLP constructs: CCL-NPB, CCL-PR1, CCL-NPB + CCL-PR1 
(mixture), CCL-PR2/N or CCL-PR2/C (see Figure 1B). ELISA endpoint IgG titers measured 
against the target peptide (Antigen) for individual animals (symbol) and the geometric mean 
(black line) after the second immunization are shown. Preimmune sera showed no reaction 
in ELISA. 
3.4. Cross-Reactivity with Strains Expressing Heterologous PspA 
The breadth of cross-reactivity of the serum IgG was tested with nine additional clinical isolates 
expressing heterologous PspA proteins and different capsular serotypes in immunoblotting and  
flow-cytometric analyses. An alignment of deduced amino acid sequences of PspA of the tested clinical 
isolates is shown in Appendix Figure A3. Sera from CCL-NPB and CCL-PR1-immunized mice cross-reacted 
with all tested clinical isolates containing a NPB (Table 1). CCL-PR1 immune sera cross-reacted with 
nine out of the 10 tested strains. CCL-PR2/C and CCL-PR2/N induced IgG that cross-reacted with eight 
of the 10 genetically diverse pneumococcal clinical isolates tested. None of the pre-immune sera were 
positive in flow-cytometry or Western blot analyses. 
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Figure 4. Cross-reactivity of sera raised against peptide-loaded SVLPs with S. pneumoniae. 
(A), competition Western blot analysis with total bacterial lysate of the S. pneumoniae 1577 
clinical isolate and the PR2/N synthetic peptide. Total lysates were separated by SDS-PAGE 
under reducing conditions and blotted onto a nitrocellulose membrane. Serum of a NMRI 
mouse immunized with CCL-PR2/N was pre-incubated with or without peptide competitor 
and subsequently added to cut strips. Immune serum was used at a dilution of 1:2000 and the 
competitor at a concentration of 1, 0.1 or 0.01 g/mL; (B), flow cytometry-based surface staining 
was performed with formalin-inactivated pneumococci (1577) using CCL-PR2/N specific 
mouse serum and fluorescently labeled secondary antibodies. The signal resulting from 
staining with pre-immune serum is shown as gray area; PspA specific signals are shown with 
a black line. Sera were used at a dilution of 1:100; (C), Rates of sero-conversion for 
immunoblotting and flow-cytometry analyses with sera from immunized mice taken after 
the second immunization with peptide-loaded SVLPs. 
3.5. Protective Capacity of Epitope-Loaded SVLPs 
The capacity of recombinant proteins containing PRR regions to confer protection against 
pneumococcal challenge has been demonstrated previously [31]. In this study, a segment of PspA 
comprising the entire NPB+PR region from strain 1577 (rPspA) was cloned, produced in E. coli and 
tested in comparison with the synthetic epitope-loaded SVLPs in a challenge model of acute infection. 
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Mice were immunized either with rPspA formulated with alum, or with PRR mimetic-loaded SVLPs, 
and then challenged intravenously with a lethal dose of S. pneumoniae strain 1577. Mice that developed 
signs of illness (ruffled fur, hunched back, paralysis or other symptoms) were euthanized. Negative 
control mice that received PBS prior to challenge died or became moribund within 24 h after challenge 
(Figure 5A). Immunization with epitope-loaded SVLPs significantly delayed onset of illness and some 
mice had not developed disease symptoms by day 14 after the challenge, at which time the experiment 
was terminated. No difference in efficacy was observed between NPB and PR1-loaded SVLPs and both 
formulations were slightly more effective than rPspA. The combination CCL-NPB + CCL-PR1  
(Figure 5A, mixture) elicited longer median survival time than rPspA but was comparable in terms of 
overall protection. 
 
Figure 5. Evaluation of the protective efficacy of peptide-loaded SVLP vaccine candidates 
in an experimental mouse infection model. NMRI outbred mice were immunized with 
recombinant PspA (rPspA) formulated with alum or with SVLPs loaded with homologous 
(A) (CCL-PL1, CCL-NPB or mixture) or heterologous (B) (CCL-PR2/N or CCL-PR2/C) 
epitopes and infected intravenously (i.v.) with 104 CFUs of serotype 1 S. pneumoniae 1577. 
Control mice received PBS prior to infection. The health status of the animals was monitored 
for 14 days post-infection. In (A), there was a statistically significant delay of time to 
morbidity of the CCL-PR1, CCL-NPB and CCL-NPB + CCL-PR1 combination groups 
compared to the PBS control group (p = 0.0143, p = 0.0027 and p = 0.0143, respectively) 
but no difference between the rPspA and the PBS group (p = 0.1336; log rank (Mantel-Cox) 
test; n = 5 mice per group). In (B), there was a statistically significant prolongation of 
survival for CCL-PR2/C immunized mice compared to PBS-treated animals (p = 0.0143) 
but no difference between the CCL-PR2/N and the PBS group (p = 0.3173; log rank  
(Mantel-Cox) test; n = 5 mice per group). 
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In order to determine the capacity of PRR epitope mimetic loaded SVLPs to confer protection against 
infection with pneumococci expressing a heterologous PRR, mice were immunized with SVLPs made 
from CCL-PR2/N and CCL-PR2/C and then challenged with 104 CFUs of S. pneumoniae 1577. 
Immunization with CCL-PR2/N was only poorly protective against lethal infection, whereas CCL-PR2/C, 
in which the PRR-derived sequence is linked to the CCL in the reverse orientation, significantly 
increased the median survival time (Figure 5B). Some immunized mice did not die or show any 
symptoms of illness during the 14 day period of observation after infection. 
3.6. Localization of Cross-Protective Epitopes in PR2 
In order to map the epitopes conferring protection in the heterologous challenge experiment, 
competition ELISA was performed using anti-sera against CCL-PR2/N and CCL-PR2/C and peptide 
competitors representing the N- and C-terminal halves of the PR2 epitope. The results showed that the 
main fraction of the vaccine-induced IgG serum antibodies were directed against epitopes located at the 
unconjugated end of each peptide antigen; that is, against the C-terminal portion of CCL-PR2/N and the 
N-terminal segment of CCL-PR2/C (Figure 6A). 
 
Figure 6. Cont. 
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Figure 6. Localization of cross-protective epitopes in PR2. (A), Epitope mapping of anti-PR2/N 
and anti-PR2/C serum antibodies by competition ELISA with peptides representing N- and 
C-terminal parts of PR2. Immune sera were used at a dilution of 1:100 and the peptide 
competitors at a concentration of 100, 10 or 0.1 μg/mL; (B), Fine mapping of epitopes 
recognized by mAbs MM-3 and MM-7. MAbs were pre-incubated with peptides representing 
amino acids 1–11, 12–21 and 1–21 of the PR2-peptide, and an Ala-scan library of the PR2 
sequence, at 10 or 100 μg/mL. Equilibrated antibody-competitor mixes were subsequently 
transferred to PR2-peptide coated ELISA plates. Bound antibody was detected using an 
alkaline phosphatase-conjugated secondary antibody; (C), Immunofluorescence staining of 
formalin-fixed S. pneumoniae 1557 with mAb MM-3 or MM-7. Surface bound IgG was 
detected with an Alexa Fluor 488-conjugated secondary antibody. Bacterial DNA was 
stained with 4,6-diamidino-2-phenylindole (DAPI). DIC, differential interference contrast 
image; (D), Mice were administered 0.5 mg of mAbs MM-3, MM-7 or PBS by i.v. injection. 
12 h later mice were infected i.v. with 104 CFUs of S. pneumoniae 1577. The health status 
of the animals was monitored and animals that developed signs of illness were euthanized, 
according to humane endpoints. There was a statistically significant delay of time to 
morbidity for MM-7-compared to PBS-treated mice (p = 0.0027) but no difference between 
the MM-3 mAb and the PBS group (p = 1; log rank (Mantel-Cox) test; n = 5 mice per group). 
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To characterize the epitopes in more detail, seven mAbs (MM-1 to MM-7) were generated from 
spleen cells taken from a CCL-PR2/N immunized mouse. The ability of the seven mAbs to bind PspA 
on streptococcal cells was analyzed by immunofluorescence microscopy. Only MM-7 cross-reacted with 
the native antigen and stained the bacterial cell surface (Figure 6C). The epitopes recognized by the 
mAbs MM-1 to MM-7 were mapped by competitive ELISA, using PR2-coated ELISA plates and 
competing peptides, including shortened peptides representing either amino acids 1–11 or 12–21 of PR2, 
as well as a panel of 18 synthetic 21-mer peptides representing an alanine scan of the PR2 sequence 
(Figure 6B). In this way, mAbs MM-1 to MM-6 were shown to bind to the C-terminal part and only the 
S. pneumoniae cross-reactive mAb MM-7 to the N-terminal part of PR2. Representative results for mAbs 
MM-3 and MM-7 are shown in Figure 6B. Moreover, the alanine-scan identified key residues in each 
motif that are important for binding to these two antibodies (see Figure 6B). These include KPEKP for 
binding MM-3, and KPEQP for recognition by MM-7. 
3.7. Protection by Passive Transfer of Anti-PspA mAbs 
Passive immunoprotection experiments were performed to test the protective efficacy of the  
seven mAbs against challenge with S. pneumoniae 1577. Purified mAbs formulated in PBS were 
administered to mice intravenously 12 h before infection with 104 CFUs. Control mice received PBS 12 
h prior to the challenge. Only mAb MM-7 was able to mediate partial protection against infection in this 
assay (Figure 6D). Hence, the N-terminal region of PR2 centered on the residues KPEQP was identified 
as a key protective epitope. It is notable that antibodies to this region of PR2 are elicited by CCL-PR2/C 
(Figure 6A), which also showed significant protective effects in the heterologous challenge model 
(Figure 5B). This motif is also present in the PR1 mimetic, which also showed significant protection in 
the homologous challenge study (Figure 5A). 
4. Discussion 
The main goal of this study was to explore the ability of SVLPs carrying synthetic epitopes from 
PspA to elicit protective humoral immune responses to a lethal S. pneumoniae infection in mice.  
Earlier studies had established that epitope-loaded SVLPs elicit very high titres of epitope-specific 
antibody responses without the need for co-administration of an adjuvant [19,20,22]. The B cell epitopes 
studied were derived from the circumsporozoite protein of the malaria parasite Plasmodium falciparum 
and from the gp120/gp41 surface spike on HIV-1. The adjuvant-independence of the strong  
pathogen-specific immune responses observed likely results from the properties of the SVLPs, which 
include multivalent surface display of B cell epitopes, multivalent T cell epitopes, as well as a lipidic 
group (the TLR2 ligand Pam2Cys) in the inner core of each nanoparticle. In this work, we focus on the 
bacterial pathogen S. pneumoniae, which provides an opportunity to address an important vaccine target 
pathogen and to exploit well-established in vitro and in vivo methods to demonstrate that a designed SVLP 
vaccine candidate can be protective in both active and passive mouse challenge experiments. This is an 
important step in exploring the potential of SVLPs for vaccine discovery and development. 
PspA is a surface-associated choline-binding protein that is present in essentially all known clinical 
isolates. A bioinformatic analysis grouped known PspAs into three families and six clades; clades 1/2 in 
family one, clades 3/4/5 in family two, and clade 6 in family three [30]. PspA is immunogenic and 
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despite numerous sequence variations remarkably cross-reactive between isolates. Most PspAs share 
many identical short stretches of amino acids, particularly in the PRR. Further cross-reactivity between 
pneumococci may also arise due to PRRs with similar short conserved motifs (such as PAPAP, PKP, or 
PEKP) present in the closely related surface virulence protein PspC [30,32,41]. 
PspA is attached to the pneumococcal surface through non-covalent interactions of its C-terminal 
choline-binding domain with teichoic acid or lipoteichoic acid in the cell membrane [42,43]. The PRR 
links the choline-binding domain with the N-terminal helical domain exposed on the pneumococcal 
surface, where it can bind and thereby block the membrane-disruptive antimicrobial activity of human 
lactoferrin [29,40]. Although the PRR threads through the thick peptidoglycan and capsule layers, at 
least portions of the PRR must be exposed and accessible to circulating antibodies [31]. The high proline 
content and frequent occurrence of repeated PXP and PXXP motifs suggests that this region might adopt 
extended polyproline-II conformations [44], an idea supported by circular dichroism studies of peptides 
from the PRR of the -protein from group B streptococci [45]. The PRR region is therefore an attractive 
target for peptide vaccine design, using linear peptides, which will likely not be required to adopt a 
compact folded conformation. Hence, for our studies, linear peptides were used, derived from the NPB 
and the PRR of the challenge strain 1577 (NPB and PR1, Figure 1B), as well as the PRR from a 
heterologous strain (PR2). 
All SVLP formulations were immunogenic in outbred mice and elicited IgG responses reactive with 
the synthetic peptides. Moreover, different peptides on separate SVLPs could be combined in one 
administration without interfering with individual anti-peptide antibody titers. The antisera contained 
antibodies binding to PspA in total lysates of the pneumococci in Western blotting analyses (Figure 4A), 
and stained cells upon flow cytometry analysis, showing that exposed epitopes are recognized on the 
surface of the bacteria. In both the homologous and heterologous challenge studies involving active 
immunizations, significant protection was observed for each of the peptide antigens tested (Figure 5). 
Moreover, in the homologous challenge experiment, under the conditions used here, the level of 
protection elicited by the SVLPs was at least as high if not higher than that using rPspA as immunogen 
with alum adjuvant (Figure 5A). 
To further characterize epitopes mediating protection, spleen cells of one of the mice immunized with 
CCL-PR2/N were used to generate monoclonal antibodies. Of the seven mAbs produced (MM-1 to MM-
7), only one (MM-7) cross-reacted with the native antigen by FACS analysis, and upon passive transfer 
and challenge with the bacterium, only MM-7 was able to confer partial protection in mice (Figure 6D). 
Interestingly, more detailed mapping studies with an Ala-scan library of peptides revealed that residues 
important for recognition by this mAb are located in a motif (PKPEQP) close to the N-terminus of the 
PR2 peptide (Figure 6B). Although Ab recognition of some epitopes may be influenced by the mode of 
peptide surface adsorption during ELISA, the results obtained are complementary to those reported by 
Daniels, et al. [31], studying immune responses from rPspA fragments, who also identified the PKPEQ 
motif in the PRR as a mediator of protection against S. pneumoniae. However, the epitope mapping 
studies reported here also show (Figure 6A) that vaccine-induced IgG serum antibodies were directed 
mostly against epitopes located at the unconjugated end of the peptide antigens, i.e., against the regions 
that should be more exposed on the surface of the nanoparticle. It seems likely, therefore, that antibodies 
directed towards this protective PKPEQP epitope might be more efficiently elicited by the PR2/C 
immunogen, than by PR2/N. It is also notable that this epitope is present near the N-terminus of the PR1 
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peptide immunogen, although likely not in an optimal location since again this peptide was N-conjugated 
to the CCL. 
Since pneumococci are genetically highly diverse and capable of rapid recombinational changes [46], 
it is generally assumed that an effective pneumococcal subunit vaccine should incorporate multiple 
protective epitopes into a single vaccine formulation. Future efforts will therefore focus on identifying 
additional components that can be incorporated into an SVLP-based streptococcal vaccine candidate. 
5. Conclusions 
We have shown that linear epitopes derived from the proline-rich region of pneumococcal surface 
protein A can be incorporated in multiple copies onto the surface of self-adjuvanting synthetic 
lipopeptide-based nanoparticles (called here synthetic virus-like particles (SVLPs)). In this format, the 
epitopes are highly immunogenic and elicit strong humoral immune responses in mice without use of an 
additional adjuvant. The results further show that following active immunization and challenge with 
lethal doses of streptococcus, these SVLP-based immunogens elicit significant protection in mice, and 
therefore may have potential for the development of an effective synthetic vaccine against Streptococcus 
pneumoniae. 
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Appendix 
 
Figure A1. The amino acid sequence of the fusion protein (rPspA), comprising the PRR of 
PspA linked to thioredoxin (Trx). The PRR is bold and underlined. 
Table A1. PCR primers used for sequencing pspA from clinical isolates (see Table 1). 
Primer Sequence 
PspA1 GCAAAAGTAGTGTCTTTATCTTTTTGG 
PspA2 CCAGCGTCGCTATCTTAGGGGCTGGTT 
PspA3 CGAACATAAATCTATTCAATCGAACC 
PspA4 AATCAACACCACCACTCATCC 
PspA5 ACCACATACCGTTTTCTTGTTTCC 
PspA6 TGGAAACAAGAAAACGGTATGTGG 
PspA7 CGAACATAAATCTATTCAATCGAACC 
PspA8 AGGTCGTGTGTGCTTCACG 
PspA9 GGAAACAAGAAAACGGTATGTGGT 
PspA10 TCAACAAGCTGAAGAAGACTATGC 
PspA11 AATGAGTTAGGCCCTGATGG 
PspA12 CGGCTTAAACCCATTCACC 
PspA13 TCTCCATCTTTCACCCAACC 
PspA14 AATGAGTTAGGCCCTGATGG 
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Figure A2. Maximum likelihood phylogenetic tree of the PRR sequences of 10 S. pneumoniae 
clinical isolates (marked with a red dot) and of 44 S. pneumoniae genomes from the NCBI 
database using a general time-reversible (GTR) substitution model with  correction for 
among-site rate variation. The branches are annotated with their bootstrap support (numbers 
in the branch). Marked pneumococcal clinical isolates were tested for their cross-reactivity 
with serum IgG antibodies induced upon immunization with epitope-loaded SVLPs. Colored 
branches correspond to pspA allelic variants that have been classified into clades according 
to Hollingshead SK et al. [30], green: clade 3; orange: clade 1; pink: clade 2; blue: clade 5; 
black: clade 4). 
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Figure A3. Cont. 
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Figure A3. Alignment of deduced amino acid sequences of PspA of the tested S. pneumoniae 
clinical isolates. The alignment was performed with Multalin (http://multalin.toulouse. 
inra.fr/multalin/multalin.html). Gaps were inserted to give the best fit. 
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